Skip to main content
Barriers to Treat-to-Target in Rheumatoid Arthritis

A systematic and scoping literature examined the Treat-to-target (

Dr. John Cush RheumNow

2 years 2 months ago
Barriers to Treat-to-Target in Rheumatoid Arthritis A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation. https://t.co/CMEd62BfU0 https://t.co/YHQ408No4S
Economic, Personal Burden of RA: Maybe Not So Bad?

Data from a major federal survey indicate that people with RA don't

Dr. John Cush RheumNow

2 years 2 months ago
Economic, Personal Burden of RA: Maybe Not So Bad? Data from a major federal survey indicate that people with RA don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found. https://t.co/ZFw7KZ0Wsb https://t.co/bO02YbzWvb
NEJM Clinical Images: Coup de Sabre (linear scleroderma) 70-year-old woman with a history of hypothyroidism presented to

Dr. John Cush RheumNow

2 years 2 months ago
NEJM Clinical Images: Coup de Sabre (linear scleroderma) 70-year-old woman with a history of hypothyroidism presented to the dermatology clinic with a 1-year history of progressive indentation and darkening of the skin of her forehead https://t.co/RiVNQiy5MM https://t.co/pxVEqBIUWP
A new scientific review of 148 studies enrolling over 4.3 million adult chronic pain patients treated with prescription opioid painkillers has found that nearly one in ten patients experiences opioid dependence or opioid use disorder and nearly one in three shows symptoms of dependence and opioid use disorder.
CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis

CARRA has developed consensus treatment plans (CTPs)

Dr. John Cush RheumNow

2 years 2 months ago
CARRA Consensus Treatment for Refractory Juvenile Dermatomyositis CARRA has developed consensus treatment plans (CTPs) for the use of bDMARDs in patients with refractory, moderately severe juvenile dermatomyositis (JDM). https://t.co/NKikKGxlOY https://t.co/aJk8t5JTip
Gout Forecast: 70% Increase by 2050

The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) of 2021 has

Dr. John Cush RheumNow

2 years 2 months ago
Gout Forecast: 70% Increase by 2050 The Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) of 2021 has forecasted prevalence of gout to increase by 70% by 2050. https://t.co/7OSQXSBtUc https://t.co/p9hkO5xzAa
Maksymowych and colleagues have shown that screening patients with either psoriasis, iritis, or colitis may yield a surprising percentage meeting ASAS criterial for axial spondyloarthritis (axSpA).
Real-world, retrospective study of microscopic-polyangiitis (ΜPA) and granulomatosis-with-polyangiitis (GPA) patients shows that rituximab (RTX) maintenance was associated with 25% risk of relapse and that lower relapse rates was seen with RTX plus cyclophosphamide treatment.
UK Biobank 11+ yr study of 5728 incident gout pts - light alcohol decreased in gout incidence among females (HR 0.78). L

Dr. John Cush RheumNow

2 years 2 months ago
UK Biobank 11+ yr study of 5728 incident gout pts - light alcohol decreased in gout incidence among females (HR 0.78). Light red wine also reduced gout risk, whereas beer or cider, champagne or white wine, and spirits increased the gout risk at any dose. https://t.co/nP8vObFsOH https://t.co/DuXQMyeaE3
Pt Reported Outcomes in axSpA or PsA may be interpreted differently if fibromyalgia is present. ASDAS-CRP, & duratio

Dr. John Cush RheumNow

2 years 2 months ago
Pt Reported Outcomes in axSpA or PsA may be interpreted differently if fibromyalgia is present. ASDAS-CRP, & duration of lumbar AM stiffness were not affected by FM, yet FM significantly caused higher scores in axSpA or PsA all assessments https://t.co/v8wFzIVxUr https://t.co/eIXRoktYja
Lead with Lupus (8.2.2024)

Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S

Dr. John Cush RheumNow

2 years 2 months ago
Lead with Lupus (8.2.2024) Dr. Jack Cush reviews the news and journal reports from this past week on https://t.co/V10S4oVFsv - leading with lupus because everyone wants to know about lupus! https://t.co/kzoijNGyfd https://t.co/S2llbb0pMO
FDA issued draft guidance, which, if implemented, would remove requirement for a switching study for demonstrating biosi

Dr. John Cush RheumNow

2 years 2 months ago
FDA issued draft guidance, which, if implemented, would remove requirement for a switching study for demonstrating biosimilar interchangeability. Citing research showing no additional safety concerns if pts switched from reference biologics to biosimilars https://t.co/MBvI4yxajW https://t.co/sEE654E2rl
Economic, Personal Burden of RA: Maybe Not So Bad?
  • MedPage Today
Data from a major federal survey indicate that people with rheumatoid arthritis (RA) don't pay massively more for healthcare than other folks, nor is their risk for functional deficits tremendously greater, researchers found.
A systematic and scoping literature examined the Treat-to-target (T2T) approach to rheumatoid arthritis (RA), noting its implementation is suboptimal and finding many barriers to implementation.
×